NAFLD or NASH

NAFLD or NASH

New NAFLD or NASH content for you

Tags: Webinar NASH genetics

Webinar: An insider’s view on drug development in NASH

If you missed our live webinar, you can catch up on the discussion about the NASH therapy landscape by watching the video recording.

Read more

Precision Pioneers EP 5: Alnylam's Josh Friedman on developing precision medicines for the 'silent killer' NASH/NAFLD

Insights & Information

NAFLD or NASH Prevalence

NAFLD affects approximately 1 in 4 people on a global scale.

NAFLD is highly prevalent on a global scale, but the highest rates are reported in South America and the Middle East, followed by Asia, the USA and Europe. [1]

Genetics

Genetically, NAFLD is complex, although it does have a consistent association with one gene PNPLA3, in European populations. Researchers are calling for further studies to investigate the genetics of NAFLD in diverse populations. [2]

The heritability of NAFLD or NASH is medium - 20% - 70% [3]

Main Symptoms

aching pain in the top right of the tummy
extreme tiredness
unexplained weight-loss
weakness

Early stage NAFLD is usually symptom-less and will only become apparent if diagnosed during tests carried out for another reason. Patients with NASH (a more advanced form of NAFLD) can sometimes experience the above symptoms. [4]

Impacts

Development of NAFLD is closely linked to lifestyle factors, including poor diet and lack of regular exercise. There is currently no drug therapy available for treatment of NAFLD. [5]

It’s estimated that the more advanced form of NAFLD, NASH, will be the most common reason for liver transplants in the USA by 2030. [6]

Resources for advice

These are the best resources we've found so far on managing and learning about NAFLD or NASH . Please let us know if you have other and we'll add them to the list!

Share this page to help us reach more people, build a better information set, and move research forward!